Do extremely large goiters carry a higher risk of malignancy or complications? A case control study.

Goiter Thyroid Thyroidectomy cancer

Journal

American journal of otolaryngology
ISSN: 1532-818X
Titre abrégé: Am J Otolaryngol
Pays: United States
ID NLM: 8000029

Informations de publication

Date de publication:
03 Apr 2024
Historique:
received: 31 12 2023
accepted: 01 04 2024
medline: 17 4 2024
pubmed: 17 4 2024
entrez: 16 4 2024
Statut: aheadofprint

Résumé

The definition of thyroid goiter remains ambiguous, yet size may impact both malignancy rate and surgical complications' rate. All patients with thyroid goiter who underwent thyroidectomy between 1/2015-1/2023 were included. Goiter was defined as lobe ≥4 cm. For analysis purpose, goiters measuring 4-8 cm and ≥8 cm were defined as large and extremely large goiters, respectively. For malignancy definition, tumor<1 cm in their largest diameter were excluded from study. Collected data included demographics, cytology, histology and postoperative complication. 144 goiters from 111 patients were included. The most common indication for surgery was symptoms (55 %). Compared with large goiter, extremely large goiters demonstrated a trend for tracheal narrowing on pre-operative CT findings (23 % vs. 45 %, p = 0.07 respectively). Overall differentiated thyroid carcinoma (DTC) rate was 17 % (25/144) without statistical difference between groups (p = 0.89). Within goiters with pre-operative benign cytology, the DTC rate was 17 % (7/43). Follicular variant of papillary thyroid cancer was the most common type for both groups. Nodular hyperplasia was significantly associated with extremely large goiters (53 % vs. 73 %, p = 0.03). No significant difference was found in transient hypocalcemia (48 % [15/31] vs. 41 % [5/12], p = 0.6) and other complications' rate between extremely large goiters and the control group. When discussing management options for patients with goiters, the size of the goiter should not regarded as a higher risk for complications or malignancy, yet the relatively high malignancy rate found should be taken under consideration for resection.

Identifiants

pubmed: 38626601
pii: S0196-0709(24)00069-3
doi: 10.1016/j.amjoto.2024.104283
pii:
doi:

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

104283

Informations de copyright

Copyright © 2024 Elsevier Inc. All rights reserved.

Déclaration de conflit d'intérêts

Declaration of competing interest The authors declare they have no competing interest and received no funding for the study.

Auteurs

Chen Hazout (C)

Department of Otolaryngology Head and Neck Surgery, Soroka University Medical Center, Israel; Faculty of Health sciences, Ben Gurion University of the Negev, Beer Sheva, Israel. Electronic address: Hazout6@gmail.com.

Aviv Daniel (A)

Department of Otolaryngology Head and Neck Surgery, Soroka University Medical Center, Israel; Faculty of Health sciences, Ben Gurion University of the Negev, Beer Sheva, Israel.

Oren Ziv (O)

Department of Otolaryngology Head and Neck Surgery, Soroka University Medical Center, Israel; Faculty of Health sciences, Ben Gurion University of the Negev, Beer Sheva, Israel.

Uri Yoel (U)

Faculty of Health sciences, Ben Gurion University of the Negev, Beer Sheva, Israel; Unit of Endocrinology, Soroka University Medical Center, Beer Sheva, Israel.

David Kiderman (D)

Department of Otolaryngology Head and Neck Surgery, Kaplan Medical Center, Israel; Hebrew University in Jerusalem, Rehovot, Israel.

Rami Shukrun (R)

Department of Otolaryngology Head and Neck Surgery, Soroka University Medical Center, Israel; Faculty of Health sciences, Ben Gurion University of the Negev, Beer Sheva, Israel.

Oded Cohen (O)

Department of Otolaryngology Head and Neck Surgery, Soroka University Medical Center, Israel; Faculty of Health sciences, Ben Gurion University of the Negev, Beer Sheva, Israel; Department of Otolaryngology-Head and Neck Surgery, Samson Assuta Ashdod University Hospital, Ashdod, Israel.

Classifications MeSH